Top Tweets for #imMotion151
Beautiful commentary - I particularly like the figure below that juxtaposes data from #IMmotion151 from @motzermd et al against data from #JAVELIN100 from @ReneeSaliby @DrChoueiri @BraunMDPhD et al. Very nicely done, @chadihc98 @neerajaiims @huntsmancancer!
Just in @Cancer_Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer: Excellent commentary highlighting these biomarkers by our fellow @chadihc98 👇https://t.co/6FT646QLW5 @Huntsman_GU @OncoAlert @urotoday @kidneycan
Proud mentor @DrChoueiri overseeing two stars, @Chrislabaki1 & @ReneeSaliby, during #KCRS22. Amazing to see the opportunities he has given @DanaFarber fellows over the years! Terrific data re: pushing #Immotion151 sigs into #JR101 & #chromophobe #kidneycancer.
In the phase III #IMmotion151 trial of metastatic #RenalCellCarcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. #ReadNow on UroToday > https://t.co/q4vIPEX7Bo @Annals_Oncology @UniklinikBonn @IEO_HolzelLab
In the phase III #IMmotion151 trial of metastatic #RenalCellCarcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. #ReadNow on UroToday > https://t.co/q4vIPEFwcO @Annals_Oncology @UniklinikBonn @IEO_HolzelLab
#IMmotion151 subgroup analysis. Pts w/ mRCC - patients with sarcomatoid features had increased overall survival with atezo+bev vs sunitinib, regardless of PD-L1 status. @brian_rini @ClevelandClinic. Coverage by @TheRealJasonZhu @DukeCancer on UroToday. https://t.co/38ipUOxpax
On the other hand, PD-L1 expression didn't predict benefit on single agent Nivolumab but correlated with better outcomes in patients receiving ICI combinations (#CheckMate-214, #KEYNOTE-426, #IMmotion151, #JAVELINRENAL101).
Role of PD-L1 as a biomarker --> still controversial.
#IMmotion151 subgroup analysis. Pts w/ mRCC - patients with sarcomatoid features had increased overall survival with atezo+bev vs sunitinib, regardless of PD-L1 status. @brian_rini @ClevelandClinic. Coverage by @TheRealJasonZhu @DukeCancer on UroToday. https://t.co/38ipUOxpax
The challenges faced by established frontline therapies in renal cancer. @AlbigesL @GustaveRoussy #Checkmate214, #IMmotion151, and #JAVELIN101, #Keynote426 @GoldbergHanan @pmcancercentre covers: https://t.co/2OvKLANdus
#IMmotion151 update in @TheLancet: Atezolizumab plus Bevacizumab versus Sunitinib in mRCC. Prolonged PFS with A+B, but no significant improvement in OS. Slightly better toxicity profiles. What's next? #clinicaltrials #cancer #Immunotherapy https://t.co/Q3DpIMiDct
Also from @EMA_News last week: Withdrawal of application for a change to the marketing authorisation for Tecentriq (atezolizumab) - (plus bev) pending additional data collection from ongoing trial #kidneycancer #imMotion151 https://t.co/xon6OLnJbW
We had a chance to ask Dr. Rini from @ClevelandClinic to discuss subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma at #ESMO18. Check it out this quick clip from our interview here: https://t.co/Ac91h2ee2H
#KidneyCancer #kcsm #Immotion151
.@DrChoueiri , Director of the Lank Center for GU Oncology at @DanaFarber , shares top abstracts in #genitourinary #oncology presented at ASCO 2018, such as #IMmotion151, the #PROSPER trial, #Carmena, and more! Live now on @OncologyGo. https://t.co/tD1y9kbWQv
Trial updates in #mRCC from ASCO: KEYNOTE-427, RESORT, #E2810 & #IMmotion151 @DrChoueiri @DanaFarber @VJOncology #ASCO18 https://t.co/JItNIOxCed
#ASCO18 news: #IMmotion151 patient-reported outcomes add support for first-line #atezolizumab plus #bevacizumab in patients with metastatic #RCC. #kidneycancer Reported by Bernard Escudier @ASCO https://t.co/P5KK1R7Y8X
Not all #IO equal for #kidneycancer? No OS benefit so far for atezo/bev in #IMMOTION151. Did include sarcomatoid RCC, sunitinib arm might be fraction worse than #CHECKMATE214 @IKCCorg @ANZUPtrials @ASCO #GU18
Last Seen Hashtags on Sotwe
spycam
Seen from Turkey
kapaklı
Seen from Turkey
podolatria
Seen from Brazil
RejectG20TaxDeal
Seen from United States
borutouzumaki sex
Seen from Venezuela
mgai
Seen from United States
balochisex
Seen from Pakistan
グラビア
Seen from Switzerland
glovefetish
Seen from United States
VGKKIDS
Seen from Malaysia
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers